Galanthamine treatment in Alzheimer’s disease

Dal‐Bianco, Peter; Maly, Joachim; Wöber, Christian; Lind, Charlotta; Koch, Giacomo; Hufgard, J.; Marschall, I.; Mráz, Marek; Deecke, Lüder

doi:10.1007/978-3-7091-9135-4_10

Cited by 22 publications

(15 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are some clinical trials not included in the review. For instance, the study carried out by Dal-Bianco et al (1991) was excluded since it did not employ the internationally standardised testing methods, such as ADAS or MMSE. Another clinical trial (Gal-93-03) was also excluded due to lack of information available for further investigation (Raskind et al, 2000).…”

Section: Clinical Trials Included In This Reviewmentioning

confidence: 99%

Galanthamine from snowdrop—the development of a modern drug against Alzheimer’s disease from local Caucasian knowledge

Heinrich

Teoh

2004

Journal of Ethnopharmacology

477

286

View full text Add to dashboard Cite

Section: Clinical Trials Included In This Reviewmentioning

confidence: 99%

Galanthamine from snowdrop—the development of a modern drug against Alzheimer’s disease from local Caucasian knowledge

Heinrich

Teoh

2004

Journal of Ethnopharmacology

477

286

View full text Add to dashboard Cite

“…On the basis of early observations of ef®cacy in AD (Rainer et al, 1989;Dal-Bianco et al, 1991;Wilcock et al, 1993;Kewitz et al, 1994), this Phase II study was undertaken to determine the ef®cacy and tolerability of three different dosages of galantamine (18,24 and 36 mg/day) administered for 3 months in patients with mild-to-moderate AD.…”

Section: Introductionmentioning

confidence: 99%

Galantamine: a randomized, double‐blind, dose comparison in patients with Alzheimer's disease

Wilkinson

Murray²

2001

Int J Geriat Psychiatry

189

123

View full text Add to dashboard Cite

show abstract

“…Galantamine, a novel treatment for AD, has a dual mechanism of action, combining allosteric modulation of nicotinic acetylcholine receptors with reversible, competitive inhibition of acetylcholinesterase (11). On the basis of these studies, galantamine provides a broad spectrum of benefits in cognition, global function and activities of daily living in AD patients, but no studies have been conducted in Thai patients before (12–15).…”

Section: Introductionmentioning

confidence: 99%

Efficacy study of galantamine in possible Alzheimer's disease with or without cerebrovascular disease and vascular dementia in Thai patients: a slow-titration regimen

Thavichachart

Phanthumchinda

Chankrachang

et al. 2006

International Journal of Clinical Practice

View full text Add to dashboard Cite

OnlineOpen: This article is available free online at www.blackwell-synergy.com S U M M A R YThe objective is to evaluate the efficacy of galantamine when a slow titration regimen is employed in Thai Alzheimer's disease (AD) patients with or without cerebrovascular disease and vascular dementia (VaD).A 6-month, multicentre, open-label, uncontrolled trial was undertaken in 75 AD patients. Eligible patients received an initial galantamine dose of 8 mg/day and escalated over 5-8 weeks to maintenance doses of 16 or 24 mg/day. Primary efficacy measures were AD Assessment Scale-cognitive subscale (ADAS-cog) and the Clinician's Interview-Based Impression of Change-Plus version (CIBIC-plus). The Behavioural Pathology in AD Rating Scale (BEHAVE AD), the AD Cooperative Study Activities of Daily Living Inventory and Pittsburgh Sleep Quality Index were the secondary efficacy variables. Analyses were based on the intent-to-treat population.Treatment with galantamine showed significant improvement in cognition on the ADAS-cog and CIBIC-plus at month 6. Galantamine showed favourable effects on activities of daily living. Behavioural symptoms and sleep quality were also significantly improved (p < 0.05). Galantamine was well tolerated. The adverse events were mild-to-moderate intensity. The most frequent adverse events commonly reported were nausea (16.4%), dizziness (9.6%) and vomiting (6.8%).The results of this study may be consistent with galantamine being an effective and safe treatment for mildto-moderate AD patients with or without cerebrovascular disease and VaD. Flexible dose escalation of galantamine was well tolerated. The daily maintenance dose of galantamine was 16 mg/day, followed by a back up dose of 24 mg/day.

show abstract

Galanthamine treatment in Alzheimer’s disease

Cited by 22 publications

References 8 publications

Galanthamine from snowdrop—the development of a modern drug against Alzheimer’s disease from local Caucasian knowledge

Galanthamine from snowdrop—the development of a modern drug against Alzheimer’s disease from local Caucasian knowledge

Galantamine: a randomized, double‐blind, dose comparison in patients with Alzheimer's disease

Efficacy study of galantamine in possible Alzheimer's disease with or without cerebrovascular disease and vascular dementia in Thai patients: a slow-titration regimen

Contact Info

Product

Resources

About